01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
glp 1 agonist retatrutide Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide 10mg Triple Agonist |
Description
The approval marks the first new biologic treatment option for HS in almost a decade, according to Novartis announcement
It contributes to mobility and fall prevention, allowing people to move confidently, react quickly, and maintain balance
doi: 10.1111/bcpt.12962
Fibroblast growth factor 21 mediates specific glucagon actions
The GLP-1 market is projected to reach an estimated 31.5 million users by 2035
